Poor
Not Aligned
Patient Risk:
Low
Summary
The AI statements largely make efficacy/outcome and dosing/maintenance timing claims specific to eosinophilic esophagitis, but the provided FDA label excerpts do not include any corresponding EoE clinical study results, remission/swallowing/impaction outcomes, duration after stopping, or combination/avoidance statements for EoE. Several statements are therefore unsupported relative to the provided label text.
Category Scores
Accurate Statements
Unsupported Statements
Dupixent (dupilumab) reduces esophageal inflammation in eosinophilic esophagitis.
No EoE-specific efficacy endpoint (e.g., reduction of esophageal inflammation) is present in the provided label excerpts.
Dupixent (dupilumab) improves swallowing in many patients with eosinophilic esophagitis.
No EoE swallowing outcome claims (e.g., symptom improvement or swallowing improvement magnitude) appear in the provided label excerpts.
In clinical trials, 60 percent of patients on the 300 mg weekly dose achieved histologic remission after 24 weeks.
No EoE trial results, remission rates, dose-specific (300 mg weekly) data, or 24-week histologic remission percentages appear in the provided label excerpts.
In clinical trials, 6 percent of patients on placebo achieved histologic remission after 24 weeks.
No EoE placebo-controlled histologic remission rates (including 6% at 24 weeks) appear in the provided label excerpts.
Symptom scores improve with Dupixent in eosinophilic esophagitis.
No EoE symptom score improvement data appear in the provided label excerpts.
Patients report fewer episodes of food impaction with Dupixent.
No EoE food impaction outcome data appear in the provided label excerpts.
Patients report easier swallowing with Dupixent.
No EoE swallowing-related patient-reported outcome data appear in the provided label excerpts.
Post-approval data indicate that most patients maintain histologic improvement at 12 months when they continue weekly dosing.
No post-approval or 12-month EoE maintenance data appear in the provided label excerpts.
Remission rates range from 55 to 70 percent depending on disease severity before treatment in eosinophilic esophagitis.
No EoE remission rate ranges by baseline severity appear in the provided label excerpts.
Some patients experience partial responses to Dupixent and need additional dietary changes or dilation procedures.
No label excerpt provided contains EoE response categorization or guidance that patients need dietary changes/dilation in relation to partial response.
Most people see symptom relief within 4 to 8 weeks with Dupixent.
No EoE time-to-symptom-relief information (4–8 weeks) appears in the provided label excerpts.
Histologic changes visible on biopsy usually appear by week 12 with Dupixent.
No EoE histologic change timing (e.g., by week 12) appears in the provided label excerpts.
Full tissue normalization can take up to 24 weeks with Dupixent.
No EoE tissue normalization timeline (up to 24 weeks) appears in the provided label excerpts.
Early responders tend to maintain benefit with consistent use of Dupixent.
No EoE responder subgroup maintenance statement appears in the provided label excerpts.
Symptoms and eosinophil counts typically return within 12 to 16 weeks after stopping Dupixent.
No EoE discontinuation effects or 12–16 week return timeline appears in the provided label excerpts.
Maintenance therapy is required for most patients to sustain remission with Dupixent.
No EoE maintenance requirement statement appears in the provided label excerpts.
No rebound worsening beyond baseline disease activity has been reported after stopping Dupixent.
No EoE discontinuation/rebound safety efficacy statement appears in the provided label excerpts.
Dupixent can be combined with proton-pump inhibitors in eosinophilic esophagitis when inflammation persists.
No EoE-specific concomitant medication guidance (including PPIs) appears in the provided label excerpts.
Dupixent can be combined with swallowed topical steroids in eosinophilic esophagitis when inflammation persists.
No EoE-specific concomitant medication guidance (including swallowed topical steroids) appears in the provided label excerpts.
Dupixent does not replace elimination diets in eosinophilic esophagitis.
No EoE label excerpt discusses elimination diets or whether Dupixent replaces them.
Many patients still follow food trigger removal to achieve deeper remission with Dupixent.
No EoE dietary strategy or food trigger removal outcome guidance appears in the provided label excerpts.
Sanofi and Regeneron jointly market Dupixent.
The provided label excerpts do not include marketing/company attribution statements.
The composition-of-matter patent in the United States expires in 2031.
The provided label excerpts do not contain patent/expiration information.
Pediatric exclusivity may extend protection until 2032.
The provided label excerpts do not contain exclusivity/protection duration information.
Contradictions
Important Omissions
EoE-specific FDA label details necessary to assess the above efficacy and outcome timing claims (e.g., endpoints, remission rates, dose regimen for EoE, time-to-response, and discontinuation/maintenance findings) are not present in the provided label excerpts.
Importance:
High
EoE-specific administration/dosing regimen details (including any stated “300 mg weekly dose”) are not provided in the label excerpts shown.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI statements mainly concern efficacy/timing and ancillary claims; the provided label excerpts that contain safety warnings/contraindications are not used by the AI response. Because no label-supported dosing/safety guidance for EoE is evaluated and several claims are unsupported, risk cannot be confirmed from label content; no direct contradiction to listed contraindications/warnings is present in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
EoE efficacy and timing (percentages, weeks to response, maintenance/discontinuation) and EoE concomitant-diet/therapy statements are not supported by the provided FDA label excerpts.
Suggested Improvement
Restrict claims to what is present in the provided label text. For EoE-related efficacy (remission rates, time-to-effect, outcomes like food impaction/swallowing, and discontinuation/maintenance), include only label-supported data and cite the relevant label study sections. Remove or qualify non-label assertions about marketing and patent/exclusivity dates unless those are present in the label excerpts.